1. World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. 2021(https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern).
2. World Health Organization. Weekly epidemiological update on COVID-19 - 21 December 2021. 2021(https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---21-december-2021).
3. BioNTech. Pfizer And BioNTech Provide Update on Omicron Variant. 2021(https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-provide-update-omicron-variant).
4. World Health Organization. Highlights from the Meeting of the Strategic Advisory Group of Experts(SAGE) on Immunization. 2021(https://cdn.who.int/media/docs/default-source/immunization/sage/2021/october/sage_oct2021_meetinghighlights.pdf?sfvrsn=3dcae610_15).
5. U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Expands Eligibility for COVID-19 Vaccine Boosters. 2021(https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-expands-eligibility-covid-19-vaccine-boosters).
6. Centers for Disease Control and Prevention. COVID-19 Vaccine Booster Shots. 2021(https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html).
7. 中国香港地区卫生署. 接种第3剂新冠疫苗的建议. 2021(https://www.covidvaccine.gov.hk/pdf/Third_dose_supplementary_sheet_SChi.pdf).
8. Dong Y, Dai T, Wei Y, et al. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther 2020;5:237.
9. Mostaghimi D, Valdez CN, Larson HT, et al. Prevention of host-to-host transmission by SARS-CoV-2 vaccines. Lancet Infect Dis 2021; doi:10.1016/S1473-3099(21)00472-2.
10. Wadhwa A, Aljabbari A, Lokras A, et al. Opportunities and Challenges in the Delivery of mRNA-based Vaccines. Pharmaceutics 2020;12:102.
11. Sahin U, Muik A, Vogler I, et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature 2021;595:572-577.
12. Ketas TJ, Chaturbhuj D, Portillo VMC, et al. Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva. Pathog Immun 2021;6:116-134.
13. Heinz FX, Stiasny K. Profiles of current COVID-19 vaccines. Wien Klin Wochenschr 2021;133:271-283.
14. Deming ME, Lyke KE. A 'mix and match' approach to SARS-CoV-2 vaccination. Nat Med 2021;27:1510-1511.
15. Shrotri M, Navaratnam AMD, Nguyen V, et al. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet 2021;398:385-387.
16. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27:1205-1211.
17. Zhu F, Guan X, Li Y, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020;396:479-488.
18. Nahass GR, Salomon-Shulman RE, Blacker G, et al. Intramuscular SARS-CoV-2 vaccines elicit varying degrees of plasma and salivary antibody responses as compared to natural infection. August 30, 2021(https://www.medrxiv.org/content/10.1101/2021.08.22.21262168v1.full-text). preprint.
19. Golob JL, Lugogo N, Lauring AS, et al. SARS-CoV-2 vaccines: a triumph of science and collaboration. JCI Insight 2021;6:e149187.
20. Rodriguez-Coira J, Sokolowska M. SARS-CoV-2 candidate vaccines - composition, mechanisms of action and stages of clinical development. Allergy 2021;76:1922-1924.
21. Keskin AU, Bolukcu S, Ciragil P, et al. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen. J Med Virol 2021. doi: 10.1002/jmv.27350.
22. Mok CKP, Cheng SMS, Chen C, et al. A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses of CoronaVac. November 03, 2021(https://www.medrxiv.org/content/10.1101/2021.11.02.21265843v1). preprint.
23. Ministry of Health, Chile. Covid-19 Vaccine EffectivenessAssessment in Chile. 2021(https://cdn.who.int/media/docs/default-source/blue-print/chile_rafael-araos_who-vr-call_25oct2021.pdf?sfvrsn=7a7ca72a_7).
24. Callaway E. Omicron likely to weaken COVID vaccine protection. Nature 2021. doi:10.1038/d41586-021-03672-3
发表评论
注册或登后即可发表评论
登录注册
全部评论(0)